Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Potential of Nintedanib in Treatment of Progressive Fibrosing Interstitial Lung Diseases

Lutz Wollin, Jörg H.W. Distler, Elizabeth F. Redente, David W. H. Riches, Susanne Stowasser, Rozsa Schlenker-Herceg, Toby M. Maher, Martin Kolb
European Respiratory Journal 2019; DOI: 10.1183/13993003.00161-2019
Lutz Wollin
1Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: stefan-lutz.wollin@boehringer-ingelheim.com
Jörg H.W. Distler
2Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth F. Redente
3Program in Cell Biology, Department of Pediatrics, National Jewish Health, Denver, Colorado, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David W. H. Riches
3Program in Cell Biology, Department of Pediatrics, National Jewish Health, Denver, Colorado, USA
4University of Colorado School of Medicine, Aurora, Colorado, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susanne Stowasser
5Boehringer Ingelheim International GmbH, Ingelheim, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rozsa Schlenker-Herceg
6Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toby M. Maher
7National Heart and Lung Institute, Imperial College London, UK, and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Kolb
8McMaster University and St. Joseph's Healthcare, Hamilton, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Martin Kolb
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

A proportion of patients with fibrosing interstitial lung diseases (ILDs) develop a progressive phenotype characterised by decline in lung function, worsening quality of life and early mortality. Other than idiopathic pulmonary fibrosis (IPF), there are no approved drugs for fibrosing ILDs and a poor evidence base to support current treatments. Fibrosing ILDs with a progressive phenotype show commonalities in clinical behaviour and in the pathogenic mechanisms that drive disease worsening. Nintedanib is an intracellular inhibitor of tyrosine kinases that has been approved for treatment of IPF and has recently been shown to reduce the rate of lung function decline in patients with ILD associated with systemic sclerosis (SSc-ILD). In vitro data demonstrate that nintedanib inhibits several steps in the initiation and progression of lung fibrosis, including the release of pro-inflammatory and pro-fibrotic mediators, migration and differentiation of fibrocytes and fibroblasts, and deposition of extracellular matrix. Nintedanib also inhibits the proliferation of vascular cells. Studies in animal models with features of fibrosing ILDs such as IPF, SSc-ILD, rheumatoid arthritis-ILD, hypersensitivity pneumonitis and silicosis demonstrate that nintedanib has anti-fibrotic activity irrespective of the trigger for the lung pathology. This suggests that nintedanib inhibits fundamental processes in the pathogenesis of fibrosis. A trial of nintedanib in patients with progressive fibrosing ILDs other than IPF (INBUILD) will report results in 2019.

Footnotes

This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.

Conflict of interest: Lutz Wollin is an employee of Boehringer Ingelheim Pharma GmbH & Co KG

Conflict of interest: Dr. Distler has nothing to disclose.

Conflict of interest: Dr. Redente has nothing to disclose.

Conflict of interest: Dr. Riches has nothing to disclose.

Conflict of interest: Susanne Stowasser is an employee of Boehringer Ingelheim International GmbH

Conflict of interest: Rozsa Schlenker-Herceg is an employee of Boehringer Ingelheim Pharmaceuticals, Inc.

Conflict of interest: Toby M Maher has, via his institution, received industry-academic funding from GlaxoSmithKline R&D and UCB; has received consultancy or speakers fees from Apellis, AstraZeneca, Bayer, Biogen Idec, Boehringer Ingelheim, Galapagos, GlaxoSmithKline R&D, Indalo, Pliant, ProMetic, Roche, Samumed and UCB; and has received consultancy fees from Galecto.

Conflict of interest: Dr. Kolb reports grants and personal fees from Roche, grants and personal fees from Boehringer Ingelheim , grants and personal fees from GSK, grants and personal fees from Gilead, grants from Actelion, grants from Respivert, personal fees from Genoa, grants from Alkermes, grants from Pharmaxis, grants and personal fees from Prometic, personal fees from Indalo, personal fees from Third Pole, outside the submitted work.

This is a PDF-only article. Please click on the PDF link above to read it.

  • Copyright ©ERS 2019
PreviousNext
Back to top
View this article with LENS
Vol 62 Issue 3 Table of Contents
European Respiratory Journal: 62 (3)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Potential of Nintedanib in Treatment of Progressive Fibrosing Interstitial Lung Diseases
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Potential of Nintedanib in Treatment of Progressive Fibrosing Interstitial Lung Diseases
Lutz Wollin, Jörg H.W. Distler, Elizabeth F. Redente, David W. H. Riches, Susanne Stowasser, Rozsa Schlenker-Herceg, Toby M. Maher, Martin Kolb
European Respiratory Journal Jan 2019, 1900161; DOI: 10.1183/13993003.00161-2019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Potential of Nintedanib in Treatment of Progressive Fibrosing Interstitial Lung Diseases
Lutz Wollin, Jörg H.W. Distler, Elizabeth F. Redente, David W. H. Riches, Susanne Stowasser, Rozsa Schlenker-Herceg, Toby M. Maher, Martin Kolb
European Respiratory Journal Jan 2019, 1900161; DOI: 10.1183/13993003.00161-2019
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • The path to TB elimination: a renewed vision
  • The paradox of immune checkpoint inhibition re-activating tuberculosis
  • The physiological basis of pulmonary arterial hypertension
Show more Review

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society